Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.

Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, Goggins M.

Gastroenterology. 2012 Apr;142(4):730-733.e9. doi: 10.1053/j.gastro.2011.12.042. Epub 2012 Jan 5.

2.

GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.

Tan MC, Basturk O, Brannon AR, Bhanot U, Scott SN, Bouvier N, LaFemina J, Jarnagin WR, Berger MF, Klimstra D, Allen PJ.

J Am Coll Surg. 2015 May;220(5):845-854.e1. doi: 10.1016/j.jamcollsurg.2014.11.029. Epub 2015 Feb 11.

3.

The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.

Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shiratori K, Shibata N, Shimizu M, Furukawa T.

J Pathol. 2013 Nov;231(3):335-41. doi: 10.1002/path.4242.

PMID:
23893889
4.

Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.

Tamura K, Ohtsuka T, Matsunaga T, Kimura H, Watanabe Y, Ideno N, Aso T, Miyazaki T, Ohuchida K, Takahata S, Ito T, Ushijima Y, Oda Y, Mizumoto K, Tanaka M.

Surgery. 2015 Feb;157(2):277-84. doi: 10.1016/j.surg.2014.09.013. Epub 2014 Dec 16.

PMID:
25530484
5.

Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.

Ideno N, Ohtsuka T, Kono H, Fujiwara K, Oda Y, Aishima S, Ito T, Ishigami K, Tokunaga S, Ohuchida K, Takahata S, Nakamura M, Mizumoto K, Tanaka M.

Ann Surg. 2013 Jul;258(1):141-51. doi: 10.1097/SLA.0b013e31828cd008.

PMID:
23532108
6.

Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.

Singhi AD, Nikiforova MN, Fasanella KE, McGrath KM, Pai RK, Ohori NP, Bartholow TL, Brand RE, Chennat JS, Lu X, Papachristou GI, Slivka A, Zeh HJ, Zureikat AH, Lee KK, Tsung A, Mantha GS, Khalid A.

Clin Cancer Res. 2014 Aug 15;20(16):4381-9. doi: 10.1158/1078-0432.CCR-14-0513. Epub 2014 Jun 17.

7.

Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor.

Murphy SJ, Hart SN, Lima JF, Kipp BR, Klebig M, Winters JL, Szabo C, Zhang L, Eckloff BW, Petersen GM, Scherer SE, Gibbs RA, McWilliams RR, Vasmatzis G, Couch FJ.

Gastroenterology. 2013 Nov;145(5):1098-1109.e1. doi: 10.1053/j.gastro.2013.07.049. Epub 2013 Aug 2.

8.

EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study.

Siddiqui AA, Kowalski TE, Kedika R, Roy A, Loren DE, Ellsworth E, Adler D, Finkelstein SD.

Gastrointest Endosc. 2013 Apr;77(4):669-70. doi: 10.1016/j.gie.2012.11.009. No abstract available.

PMID:
23498145
9.

Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.

Furukawa T, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T, Takeda K, Matsuno S, Horii A.

Mod Pathol. 2005 Aug;18(8):1034-42.

10.

Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.

Ideno N, Ohtsuka T, Matsunaga T, Kimura H, Watanabe Y, Tamura K, Aso T, Aishima S, Miyasaka Y, Ohuchida K, Ueda J, Takahata S, Oda Y, Mizumoto K, Tanaka M.

Pancreas. 2015 Mar;44(2):311-20. doi: 10.1097/MPA.0000000000000258.

PMID:
25479586
11.

Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.

Mohri D, Asaoka Y, Ijichi H, Miyabayashi K, Kudo Y, Seto M, Ohta M, Tada M, Tanaka Y, Ikenoue T, Tateishi K, Isayama H, Kanai F, Fukushima N, Tada M, Kawabe T, Omata M, Koike K.

J Gastroenterol. 2012 Feb;47(2):203-13. doi: 10.1007/s00535-011-0482-y. Epub 2011 Nov 1.

PMID:
22041919
12.

GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs".

Matthaei H, Wu J, Dal Molin M, Shi C, Perner S, Kristiansen G, Lingohr P, Kalff JC, Wolfgang CL, Kinzler KW, Vogelstein B, Maitra A, Hruban RH.

Am J Surg Pathol. 2014 Mar;38(3):360-3. doi: 10.1097/PAS.0000000000000117.

13.

Molecular pathways in pancreatic carcinogenesis.

Macgregor-Das AM, Iacobuzio-Donahue CA.

J Surg Oncol. 2013 Jan;107(1):8-14. doi: 10.1002/jso.23213. Epub 2012 Jul 17. Review.

14.

[Will molecular diagnostics become established in pancreatic pathology?].

Sipos B, Sperveslage J.

Pathologe. 2013 Nov;34 Suppl 2:214-20. doi: 10.1007/s00292-013-1865-z. Review. German.

PMID:
24196616
15.

KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.

Shi C, Hong SM, Lim P, Kamiyama H, Khan M, Anders RA, Goggins M, Hruban RH, Eshleman JR.

Mol Cancer Res. 2009 Feb;7(2):230-6. doi: 10.1158/1541-7786.MCR-08-0206. Epub 2009 Feb 10.

16.

Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs).

Koorstra JB, Feldmann G, Habbe N, Maitra A.

Langenbecks Arch Surg. 2008 Jul;393(4):561-70. doi: 10.1007/s00423-008-0282-x. Epub 2008 Feb 19. Review.

17.

Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.

Tamura K, Ohtsuka T, Ideno N, Aso T, Shindo K, Aishima S, Ohuchida K, Takahata S, Ushijima Y, Ito T, Oda Y, Mizumoto K, Tanaka M.

Ann Surg. 2014 Feb;259(2):360-8. doi: 10.1097/SLA.0b013e3182a690ff.

PMID:
23989056
18.

Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.

Schultz NA, Roslind A, Christensen IJ, Horn T, Høgdall E, Pedersen LN, Kruhøffer M, Burcharth F, Wøjdemann M, Johansen JS.

Pancreas. 2012 Jul;41(5):759-66. doi: 10.1097/MPA.0b013e31823cd9df.

PMID:
22699145
19.

Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations.

Matsubara A, Sekine S, Ogawa R, Yoshida M, Kasamatsu T, Tsuda H, Kanai Y.

Am J Surg Pathol. 2014 Mar;38(3):370-6. doi: 10.1097/PAS.0000000000000093.

PMID:
24145653
20.

GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.

Hosoda W, Sasaki E, Murakami Y, Yamao K, Shimizu Y, Yatabe Y.

Virchows Arch. 2015 Jun;466(6):665-74. doi: 10.1007/s00428-015-1751-6. Epub 2015 Mar 22.

PMID:
25796395

Supplemental Content

Support Center